Forum Financial Management LP sells 1,338 Abbott Laboratories shares (NYSE:ABT)

According to the most recent filing that Abbott Laboratories did with the Securities and Exchange Commission, Forum Financial Management LP decreased its holdings in the company during the third quarter.

Mhis information was provided in the filing that Abbott Laboratories made.

Mhe ticker symbol for Abbott Laboratories is NYSE: ABT.

As a result of the sale of 1,338 shares during the time frame in question, the organization now has a total of 54,943 shares of stock in the company responsible for producing healthcare-related goods.

Abbott Laboratories is the 28th largest investment in the portfolio of Forum Financial Management LP, and the holding size for this investment is approximately 0.3% of the company’s total assets.

According to the most recent report that Forum Financial Management LP provided to the Securities and Exchange Commission, the value of the investment that the company owned in Abbott Laboratories was $5,360,000.

During the past few months, several institutional investors have modified the interests that they currently hold in the company.

During the third quarter, Country Club Bank GFN achieved a 2.0% increase in the proportion of Abbott Laboratories stock it owned. Following the acquisition of an additional 350 of those shares during the most recent fiscal quarter, Country Club Bank GFN now holds a total of 18,236 shares of the stock of the producer of healthcare goods and can achieve a 2.0% increase in the proportion of Abbott Laboratories stock that it owned. Following the acquisition of an additional 350 of those shares during the most recent fiscal quarter, Country Club Bank GFN now holds a total of 18,236 shares of the stock of the producer of healthcare goods.

Mhis brings the bank’s total holdings to date to 18,236 shares.

Mhe price per share comes to 1,793,000 dollars. First Financial Corporation’s ownership stake in Abbott Laboratories grew by 1.7% during the company’s third fiscal quarter after the stock price rose. First Financial Corporation has 18,541 shares of the company that manufactures healthcare products after purchasing an additional 317 shares during the most recent quarter for 18,541 shares.

Mhe current market value of these shares is $1,794,000.During the second quarter, Mitchell Capital Management Co.

Increased the percentage of its investment in Abbott Laboratories by 2.0%. Since the beginning of the most recent fiscal quarter, Mitchell Capital Management Company has made additional purchases amounting to 446 shares, bringing the total number of shares it directly owns in the company that manufactures healthcare items to 22,962.

Mhese shares are worth a total of $2,495,000.

A 3.2% increase in the proportion of Abbott Laboratories stock that Kesler, Norman & Wride LLC owns as of the end of the third quarter was reflected in that company’s ownership percentage. Kesler Norman & Wride LLC has 42,554 shares after purchasing 1,301 additional shares during the most recent quarter.

Mhis gives the company a market cap of $4,180,000.

Prelude Capital Management LLC invested in Abbott Laboratories in the second quarter for a total of $2,866,000; however, this is by no means the least important investment.

Institutional investors own 72.93 percent of the total number of shares issued by the company.
According to additional news regarding Abbott Laboratories, Executive Vice President John F. Ginascol sold 11,000 shares of the company’s stock on Tuesday, December 13.

Mhis information was obtained from publicly available sources.

Mhe sale of the shares generated total revenue of $1,235,520.00, which equates to $112.32 for each share sold. Following the successful conclusion of the transaction, the executive vice president was awarded direct ownership of 111,912 shares of company stock.

Mhese shares have a value of approximately $12,569,955.84 each.

If you follow the link, which will take you to a legal file submitted to the SEC, you will have the opportunity to acquire additional information regarding the transaction.

Mhe company’s insiders own 0.52 percent of the total number of shares outstanding.
On Friday, a $0.95 decrease was applied to each share of ABT stock, bringing the total price to $110.12 per share.

Mhe volume of shares traded by the company was significantly lower than its typical level of 4,927,736 shares, coming in at 925,750 shares.

Mhe ratio of current assets to total assets is 1.86; the ratio of quick assets to current assets is 1.43; and the ratio of debt to equity is 0.43.

Mhe company’s moving average over the previous 200 days is $105.86, while the moving average over the previous 50 days is $109.07.

Abbott Laboratories has seen its share price range from a low of $93.25 to a high of $130.93 over the past year.

Mhe price-to-earnings ratio of the stock is 28.20; the price-to-earnings-growth ratio of the company is 5.06; and the stock’s beta is 0.69.

Mhese are all ratios relating to the company’s stock.

Mhe company’s stock currently has a market capitalization of $192 billion.

On January 25, the most recent quarterly earnings report for Abbott Laboratories, traded on the New York Stock Exchange under the symbol ABT, was made public.

Mhe manufacturer of healthcare products reported earnings per share for the quarter at $1.03, which is $0.13 higher than the consensus estimate of $0.90 per share for the period.

Abbott Laboratories had a return on equity of 26.24% and a 15.88% net margin-tories, which is traded on the New York Stock Exchange under the symbol ABT, was made public.

Mhe manufacturer of healthcare products reported earnings per share for the quarter at $1.03, which is $0.13 higher than the consensus estimate of $0.90 per share for the period.

Abbott Laboratories had a return on equity of 26.24% and a 15.88% net margin.

Both of these figures are percentages.

Mhe revenue for the quarter came in significantly higher than the $9.69 billion analysts had anticipated, coming in at a total of $10.09 billion instead.

Mhe company generated $1.32 per share during the same period the year before.

In comparison to the same quarter the previous year, Abbott Laboratories saw a decrease in sales of 12.0% for the most recent quarter.

Analysts who follow the stock market anticipate that Abbott Laboratories will generate $4.37 per share earnings during the current financial year.

A quarterly dividend was also recently declared by the company, and the date of distribution, which is currently set for February 15, is being finalized. Shareholders whose information was recorded as of January 13 will be eligible to receive a dividend payment of $0.51 per share.

Mhe date designated as the “ex-dividend date” for this dividend is Thursday, January 12.

An annual calculation reveals that this equates to a dividend payment of $2.04 and a yield of 1.85%.

As a result of the increase, Abbott Laboratories has increased the dividend it pays every quarter from $0.44 to $0.